A detailed history of China Universal Asset Management Co., Ltd. transactions in Exelixis, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 54,863 shares of EXEL stock, worth $1.95 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
54,863
Previous 34,222 60.32%
Holding current value
$1.95 Million
Previous $768,000 85.29%
% of portfolio
0.16%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$21.96 - $27.6 $453,276 - $569,691
20,641 Added 60.32%
54,863 $1.42 Million
Q2 2024

Jul 19, 2024

SELL
$20.34 - $23.73 $489,726 - $571,347
-24,077 Reduced 41.3%
34,222 $768,000
Q1 2024

Apr 29, 2024

BUY
$20.17 - $23.93 $450,275 - $534,213
22,324 Added 62.05%
58,299 $1.38 Million
Q4 2023

May 21, 2024

SELL
$19.25 - $24.13 $429,737 - $538,678
-22,324 Reduced 38.29%
35,975 $863,000
Q4 2023

Jan 23, 2024

BUY
$19.25 - $24.13 $535,323 - $671,031
27,809 Added 340.55%
35,975 $863,000
Q3 2023

May 21, 2024

BUY
$19.04 - $22.74 $74,217 - $88,640
3,898 Added 91.33%
8,166 $178,000
Q3 2023

Oct 30, 2023

BUY
$19.04 - $22.74 $74,217 - $88,640
3,898 Added 91.33%
8,166 $178,000
Q2 2023

May 21, 2024

SELL
$18.17 - $20.48 $2,234 - $2,519
-123 Reduced 2.8%
4,268 $81,000
Q2 2023

Jul 27, 2023

SELL
$18.17 - $20.48 $2,234 - $2,519
-123 Reduced 2.8%
4,268 $82,000
Q1 2023

May 21, 2024

BUY
$16.3 - $19.41 $18,158 - $21,622
1,114 Added 33.99%
4,391 $85,000
Q1 2023

Apr 27, 2023

BUY
$16.3 - $19.41 $18,158 - $21,622
1,114 Added 33.99%
4,391 $85,000
Q4 2022

May 21, 2024

SELL
$14.96 - $17.39 $823,129 - $956,832
-55,022 Reduced 94.38%
3,277 $52,000
Q4 2022

Jan 31, 2023

BUY
$14.96 - $17.39 $3,934 - $4,573
263 Added 8.73%
3,277 $53,000
Q3 2022

Oct 21, 2022

BUY
$15.68 - $22.27 $47,259 - $67,121
3,014 New
3,014 $47,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.